SEZABY approved by US FDA for the treatment of neonatal seizures
First and only product approved for treating neonatal seizures
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
SPARC
Sun Pharma and SPARC enter into licence agreement for commercialisation of phenobarbital for…
Product awaiting the US FDA approval, targetted at treating seizures in neonatal patients
SPARC licenses development and commercialisation rights of PDP-716 and SDN-037 to Visiox Pharma
SPARC to receive equity in Visiox along with other financial considerations
SPARC enters into licensing agreement with Biomodifying to acquire exclusive rights for antibody…
Under the agreement, Biomodifying is eligible for an upfront payment, milestone payments on pre-specified clinical, regulatory,…
SPARC declares positive results from Phase 3 clinical trial of PDP-716 to treat open-angle glaucoma…
The primary endpoint of the trial was to evaluate the efficacy of once daily (QD) dosing of PDP-716 0.35 per cent compared with…
USFDA denies application from SPARC for cancer drug
The Office of New Drugs of the US FDA requested the conduct of a new Phase 3 study in metastatic breast cancer patients to support…
Sun Pharma starts Phase II trial of SCD-044 for moderate to severe plaque psoriasis
SCD-044 is also being evaluated in other autoimmune disorders and Phase 2 studies for other indications like atopic dermatitis,…
SPARC announces Phase 3 trial results of SDN-037 to treat inflammation and pain of ocular surgery
The primary efficacy measure was the proportion of subjects with an anterior chamber cell (ACC) grade of zero (0) on Day 15 (zero…
SPARC signs license agreement with Tripoint Therapeutics for Elepsia XR tablets
SPARC will be eligible to receive tiered royalties ranging from 15 per cent to 50 per cent on net sales
SPARC and Sun Pharma enter into license agreement for SCD-044
It is a potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders